Cassava Sciences Inc
SAVA2.280USD
+0.160+7.55%
交易中 （美東）報價延遲15分鐘
110.14M總市值
虧損本益比TTM
關於 Cassava Sciences Inc 公司
Cassava Sciences, Inc. 是一家專注於神經科學的臨牀階段生物製藥公司。該公司的科學基礎是穩定而非去除阿爾茨海默氏症患者大腦中的關鍵蛋白質。其治療阿爾茨海默氏症的科學方法旨在同時抑制神經退行性病變和神經炎症。該公司正在開發兩種生物製藥資產：Simufilam 和 SavaDx。Simufilam 是其主要治療候選產品，是一種用於治療阿爾茨海默氏症癡呆症的口服藥物。Simufilam 針對的是阿爾茨海默氏症患者大腦中一種名爲細絲蛋白 A (FLNA) 的蛋白質的變異形式。該公司正在對阿爾茨海默氏症癡呆症患者進行兩項隨機安慰劑對照的口服 simufilam III 期臨牀試驗。SavaDx 是其主要研究診斷候選產品，是一種通過少量血液樣本檢測阿爾茨海默氏症存在的方法。 SavaDx 是一種僅供研究使用、與安全無關的探索性生物標誌物。
公司簡介
公司代碼SAVA
公司名稱Cassava Sciences Inc
上市日期Jul 14, 2000
CEOMr. Richard J. (Rick) Barry
員工數量30
證券類型Ordinary Share
年結日Jul 14
公司地址6801 N. Capital of Texas Highway
城市AUSTIN
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編78731
電話15125012444
網址https://www.cassavasciences.com/
公司代碼SAVA
上市日期Jul 14, 2000
CEOMr. Richard J. (Rick) Barry
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Freda Nassif
Ms. Freda Nassif
Chief Business Officer
Chief Business Officer
--
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert Anderson, Jr.
Mr. Robert Anderson, Jr.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
469.56K
+33.33%
Mr. Eric J. Schoen
Mr. Eric J. Schoen
Chief Financial Officer
Chief Financial Officer
11.50K
-35.61%
Dr. Robert Z. Gussin, Ph.D.
Dr. Robert Z. Gussin, Ph.D.
Independent Director
Independent Director
10.62K
-16.66%
Mr. Michael J. O'Donnell, Esq.
Mr. Michael J. O'Donnell, Esq.
Independent Director
Independent Director
6.87K
-16.66%
Dr. Jack Moore, Ph.D.
Dr. Jack Moore, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Patrick J. Scannon, M.D., Ph.D.
Dr. Patrick J. Scannon, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.78%
Nachtrab (Matthew)
4.69%
The Vanguard Group, Inc.
4.49%
Barbier (Remi)
4.28%
Two Sigma Investments, LP
2.81%
Other
76.95%
股東類型
持股股東
佔比
Investment Advisor
16.43%
Individual Investor
12.79%
Investment Advisor/Hedge Fund
5.95%
Research Firm
4.58%
Hedge Fund
4.46%
Bank and Trust
0.58%
Pension Fund
0.30%
Venture Capital
0.11%
Other
54.80%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
353
21.84M
45.21%
-1.76M
2025Q1
363
22.22M
46.00%
-1.56M
2024Q4
360
23.73M
49.12%
+4.41M
2024Q3
371
20.81M
43.35%
+1.72M
2024Q2
372
16.74M
35.19%
-1.63M
2024Q1
372
14.95M
34.46%
-4.56M
2023Q4
382
18.11M
42.87%
+1.40M
2023Q3
392
15.72M
37.42%
-103.08K
2023Q2
410
14.43M
34.53%
-1.76M
2023Q1
415
14.61M
34.97%
-1.98M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
3.27M
6.78%
-132.04K
-3.88%
Mar 31, 2025
Nachtrab (Matthew)
2.27M
4.69%
+2.27M
--
Aug 16, 2024
The Vanguard Group, Inc.
2.44M
5.06%
-60.35K
-2.41%
Mar 31, 2025
Barbier (Remi)
2.07M
4.28%
+727.36K
+54.36%
Sep 30, 2024
Two Sigma Investments, LP
1.36M
2.81%
+190.09K
+16.26%
Mar 31, 2025
Robertson (Sanford R)
1.34M
2.78%
-5.00K
-0.37%
May 16, 2024
Geode Capital Management, L.L.C.
1.03M
2.13%
+19.60K
+1.95%
Mar 31, 2025
State Street Global Advisors (US)
873.95K
1.81%
-122.72K
-12.31%
Mar 31, 2025
J.P. Morgan Securities LLC
749.56K
1.55%
+384.11K
+105.10%
Mar 31, 2025
Susquehanna International Group, LLP
552.02K
1.14%
+271.63K
+96.87%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
0.2%
Texas Capital Texas Small Cap Equity Index ETF
0.09%
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
ALPS Medical Breakthroughs ETF
0%
iShares Morningstar Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
Texas Capital Texas Equity Index ETF
0%
查看更多
iShares Neuroscience and Healthcare ETF
佔比0.2%
Texas Capital Texas Small Cap Equity Index ETF
佔比0.09%
iShares Micro-Cap ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0%
Texas Capital Texas Equity Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
